SALT LAKE CITY and CHARLOTTE, N.C., July 27, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named patient basis in areas outside of the United States (U.S.) where Apealea is not commercially available. Apealea has been approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
A named patient program, also known as an early or expanded access program, is a mechanism through which physicians can legally and ethically prescribe investigational or approved drugs for patients prior to their commercial availability. Under the terms of the agreement, Tanner will be the exclusive supplier of Apealea to health care providers outside of the U.S. on a named patient basis in countries where Apealea is not yet commercially available.
“We are excited to partner with Tanner to ensure patients outside of the U.S. who have no therapeutic alternatives are able to access to Apealea through a named patient program,” said Alex Kim, chief executive officer of Elevar Therapeutics.
“We are pleased to give hope to patients around the world through our partnership with Elevar for Apealea,” said Banks Bourne, chairman and founder of Tanner Pharma Group. “The named patient program will help ensure that patients who have no alternative therapeutic options for their disease receive access to Apealea in a manner that is reliable, responsible, ethical and in accordance with all local regulatory requirements.”
“We are delighted to see that patients and doctors in European countries outside the Nordic region, where Oasmia has already launched Apealea, will now get early access,” said Francois Martelet, CEO of Oasmia. “Elevar partnering with Tanner Pharma for a named patient program is a valid means to achieve that access outside of the US. We continue to support Elevar in the identification and selection of regional commercialization partners worldwide and will update our progress in due course.”
About Apealea® (paclitaxel micellar)
Apealea® is a patented, water-soluble, intravenously injectable formulation of paclitaxel, developed using Oasmia’s proprietary technology platform – XR17 – which facilitates the formulation of paclitaxel without Cremophor. Paclitaxel is a well-known chemotherapy agent used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancers. Apealea® has been authorized for marketing by the European Commission for use in combination with carboplatin in adult patients with a first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. It is Europe’s first Cremophor-free formulation of paclitaxel approved for use in ovarian cancer.
About Elevar Therapeutics
Elevar Therapeutics (formerly LSK BioPharma) is a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer. Elevar Therapeutics’ lead proprietary drug candidates include rivoceranib (apatinib), a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors, and Apealea® (paclitaxel micellar), a non-Cremophor based formulation of paclitaxel. Apealea received market authorization by the European Commission in November of 2018, making it Europe’s first Cremophor-free formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has locations in Utah, California and South Korea, and additional information is available at www.elevartherapeutics.com.
About Tanner Pharma Group
Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, USA with offices in Europe and Latin America. Over 18 years, Tanner has developed a portfolio of service offerings focused on improving the global access to medicines. Through its Managed Access Programs division, Tanner supports manufacturers by providing ethical, controlled and compliant access to their innovative medicines in countries where they are not commercially accessible. For more information, visit http://www.tannerpharma.com.
Elevar Media Contact:
Elixir Health Public Relations
Tanner Pharma Group Media Contact:
SOURCE: Elevar Therapeutics
About Tanner Pharma Group
For over 16 years, Tanner Pharma Group has partnered with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. By partnering with Tanner Pharma, biotech and pharma companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.
Tanner Pharma believes that access to medicines should have no borders and measures its value as a company based on the lives it helps to improve. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus.
Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.
For more information about Tanner Pharma Group, please visit www.tannerpharma.com.